Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid

Yvette Van Hensbergen, Henk J. Broxterman, Roeland Hanemaaijer, Anita S. Jorna, Natascha A. Van Lent, Henk M W Verheul, Herbert M. Pinedo, Klaas Hoekman

Research output: Contribution to journalArticle

Abstract

Purpose: On the basis of the finding of marked overexpression in angiogenic microvessels, aminopeptidase N/CD13 has recently been suggested to play a prominent role in tumor angiogenesis. A soluble form of CD13 (sCD13) is present in human plasma, but its role in cancer has not been addressed. We hypothesized that sCD13 would be shed by tumor cells and/or endothelial cells lining tumor vessels, giving high levels of sCD13 in intratumoral fluid (TF) deposits and in malignant effusions. If so, sCD13 could be a convenient potential marker for tumor load and/or activated tumor endothelium. Experimental Design: We have measured the specific sCD13 activity in effusions from 90 cancer patients and 12 patients with a nonmalignant condition, and studied its relationship with other major (anti-) angiogenic factors. In a separate group of patients (n = 41), the relationship of sCD13 activity in plasma with tumor load was studied. Results: The sCD13 activity was highest in plasma from cancer patients 71.9 (fmol/ml/s hydrolyzed substrate) versus 42.4 for healthy subjects. In TF, malignant effusions, and nonmalignant effusions, the activities were 52.8, 33.5, and 18.6, respectively. We further studied the relationship of sCD13 with tumor load as well as with vascular endothelial growth factor (VEGF), endostatin, matrix metalloproteinase (MMP)-2, MMP-9, urokinase-type plasminogen activator, and plasmin. A significant correlation of sCD13 activity in plasma was found with tumor load (r = 0.68; P = 0.01), suggesting that plasma sCD13 is, at least, partly originating from tumor(-endothelium). The concentrations of VEGF and endostatin and the activities of urokinase-type plasminogen activator and MMP-9, but not MMP-2, were significantly higher in TF compared with all other effusions. In TF, a correlation between sCD13 and VEGF was found (r = 0.67; P = 0.03). No correlation of sCD13 with the other protease activities was found. Conclusion: The sCD13 activity is elevated in plasma and effusions of cancer patients. A strong correlation of plasma sCD13 with tumor load was found. On the basis of these results, the potential of sCD13 activity as a tumor and/or angiogenesis marker warrants further investigation.

Original languageEnglish (US)
Pages (from-to)3747-3754
Number of pages8
JournalClinical Cancer Research
Volume8
Issue number12
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

CD13 Antigens
Tumor Burden
Neoplasms
Endostatins
Vascular Endothelial Growth Factor A
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Urokinase-Type Plasminogen Activator
Endothelium
Angiogenesis Inducing Agents
Fibrinolysin
Microvessels
Healthy Volunteers
Peptide Hydrolases
Research Design
Endothelial Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Van Hensbergen, Y., Broxterman, H. J., Hanemaaijer, R., Jorna, A. S., Van Lent, N. A., Verheul, H. M. W., ... Hoekman, K. (2002). Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clinical Cancer Research, 8(12), 3747-3754.

Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. / Van Hensbergen, Yvette; Broxterman, Henk J.; Hanemaaijer, Roeland; Jorna, Anita S.; Van Lent, Natascha A.; Verheul, Henk M W; Pinedo, Herbert M.; Hoekman, Klaas.

In: Clinical Cancer Research, Vol. 8, No. 12, 01.12.2002, p. 3747-3754.

Research output: Contribution to journalArticle

Van Hensbergen, Y, Broxterman, HJ, Hanemaaijer, R, Jorna, AS, Van Lent, NA, Verheul, HMW, Pinedo, HM & Hoekman, K 2002, 'Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid', Clinical Cancer Research, vol. 8, no. 12, pp. 3747-3754.
Van Hensbergen Y, Broxterman HJ, Hanemaaijer R, Jorna AS, Van Lent NA, Verheul HMW et al. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clinical Cancer Research. 2002 Dec 1;8(12):3747-3754.
Van Hensbergen, Yvette ; Broxterman, Henk J. ; Hanemaaijer, Roeland ; Jorna, Anita S. ; Van Lent, Natascha A. ; Verheul, Henk M W ; Pinedo, Herbert M. ; Hoekman, Klaas. / Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 12. pp. 3747-3754.
@article{24d6606a6ae24488b8a824ca16651696,
title = "Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid",
abstract = "Purpose: On the basis of the finding of marked overexpression in angiogenic microvessels, aminopeptidase N/CD13 has recently been suggested to play a prominent role in tumor angiogenesis. A soluble form of CD13 (sCD13) is present in human plasma, but its role in cancer has not been addressed. We hypothesized that sCD13 would be shed by tumor cells and/or endothelial cells lining tumor vessels, giving high levels of sCD13 in intratumoral fluid (TF) deposits and in malignant effusions. If so, sCD13 could be a convenient potential marker for tumor load and/or activated tumor endothelium. Experimental Design: We have measured the specific sCD13 activity in effusions from 90 cancer patients and 12 patients with a nonmalignant condition, and studied its relationship with other major (anti-) angiogenic factors. In a separate group of patients (n = 41), the relationship of sCD13 activity in plasma with tumor load was studied. Results: The sCD13 activity was highest in plasma from cancer patients 71.9 (fmol/ml/s hydrolyzed substrate) versus 42.4 for healthy subjects. In TF, malignant effusions, and nonmalignant effusions, the activities were 52.8, 33.5, and 18.6, respectively. We further studied the relationship of sCD13 with tumor load as well as with vascular endothelial growth factor (VEGF), endostatin, matrix metalloproteinase (MMP)-2, MMP-9, urokinase-type plasminogen activator, and plasmin. A significant correlation of sCD13 activity in plasma was found with tumor load (r = 0.68; P = 0.01), suggesting that plasma sCD13 is, at least, partly originating from tumor(-endothelium). The concentrations of VEGF and endostatin and the activities of urokinase-type plasminogen activator and MMP-9, but not MMP-2, were significantly higher in TF compared with all other effusions. In TF, a correlation between sCD13 and VEGF was found (r = 0.67; P = 0.03). No correlation of sCD13 with the other protease activities was found. Conclusion: The sCD13 activity is elevated in plasma and effusions of cancer patients. A strong correlation of plasma sCD13 with tumor load was found. On the basis of these results, the potential of sCD13 activity as a tumor and/or angiogenesis marker warrants further investigation.",
author = "{Van Hensbergen}, Yvette and Broxterman, {Henk J.} and Roeland Hanemaaijer and Jorna, {Anita S.} and {Van Lent}, {Natascha A.} and Verheul, {Henk M W} and Pinedo, {Herbert M.} and Klaas Hoekman",
year = "2002",
month = "12",
day = "1",
language = "English (US)",
volume = "8",
pages = "3747--3754",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid

AU - Van Hensbergen, Yvette

AU - Broxterman, Henk J.

AU - Hanemaaijer, Roeland

AU - Jorna, Anita S.

AU - Van Lent, Natascha A.

AU - Verheul, Henk M W

AU - Pinedo, Herbert M.

AU - Hoekman, Klaas

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Purpose: On the basis of the finding of marked overexpression in angiogenic microvessels, aminopeptidase N/CD13 has recently been suggested to play a prominent role in tumor angiogenesis. A soluble form of CD13 (sCD13) is present in human plasma, but its role in cancer has not been addressed. We hypothesized that sCD13 would be shed by tumor cells and/or endothelial cells lining tumor vessels, giving high levels of sCD13 in intratumoral fluid (TF) deposits and in malignant effusions. If so, sCD13 could be a convenient potential marker for tumor load and/or activated tumor endothelium. Experimental Design: We have measured the specific sCD13 activity in effusions from 90 cancer patients and 12 patients with a nonmalignant condition, and studied its relationship with other major (anti-) angiogenic factors. In a separate group of patients (n = 41), the relationship of sCD13 activity in plasma with tumor load was studied. Results: The sCD13 activity was highest in plasma from cancer patients 71.9 (fmol/ml/s hydrolyzed substrate) versus 42.4 for healthy subjects. In TF, malignant effusions, and nonmalignant effusions, the activities were 52.8, 33.5, and 18.6, respectively. We further studied the relationship of sCD13 with tumor load as well as with vascular endothelial growth factor (VEGF), endostatin, matrix metalloproteinase (MMP)-2, MMP-9, urokinase-type plasminogen activator, and plasmin. A significant correlation of sCD13 activity in plasma was found with tumor load (r = 0.68; P = 0.01), suggesting that plasma sCD13 is, at least, partly originating from tumor(-endothelium). The concentrations of VEGF and endostatin and the activities of urokinase-type plasminogen activator and MMP-9, but not MMP-2, were significantly higher in TF compared with all other effusions. In TF, a correlation between sCD13 and VEGF was found (r = 0.67; P = 0.03). No correlation of sCD13 with the other protease activities was found. Conclusion: The sCD13 activity is elevated in plasma and effusions of cancer patients. A strong correlation of plasma sCD13 with tumor load was found. On the basis of these results, the potential of sCD13 activity as a tumor and/or angiogenesis marker warrants further investigation.

AB - Purpose: On the basis of the finding of marked overexpression in angiogenic microvessels, aminopeptidase N/CD13 has recently been suggested to play a prominent role in tumor angiogenesis. A soluble form of CD13 (sCD13) is present in human plasma, but its role in cancer has not been addressed. We hypothesized that sCD13 would be shed by tumor cells and/or endothelial cells lining tumor vessels, giving high levels of sCD13 in intratumoral fluid (TF) deposits and in malignant effusions. If so, sCD13 could be a convenient potential marker for tumor load and/or activated tumor endothelium. Experimental Design: We have measured the specific sCD13 activity in effusions from 90 cancer patients and 12 patients with a nonmalignant condition, and studied its relationship with other major (anti-) angiogenic factors. In a separate group of patients (n = 41), the relationship of sCD13 activity in plasma with tumor load was studied. Results: The sCD13 activity was highest in plasma from cancer patients 71.9 (fmol/ml/s hydrolyzed substrate) versus 42.4 for healthy subjects. In TF, malignant effusions, and nonmalignant effusions, the activities were 52.8, 33.5, and 18.6, respectively. We further studied the relationship of sCD13 with tumor load as well as with vascular endothelial growth factor (VEGF), endostatin, matrix metalloproteinase (MMP)-2, MMP-9, urokinase-type plasminogen activator, and plasmin. A significant correlation of sCD13 activity in plasma was found with tumor load (r = 0.68; P = 0.01), suggesting that plasma sCD13 is, at least, partly originating from tumor(-endothelium). The concentrations of VEGF and endostatin and the activities of urokinase-type plasminogen activator and MMP-9, but not MMP-2, were significantly higher in TF compared with all other effusions. In TF, a correlation between sCD13 and VEGF was found (r = 0.67; P = 0.03). No correlation of sCD13 with the other protease activities was found. Conclusion: The sCD13 activity is elevated in plasma and effusions of cancer patients. A strong correlation of plasma sCD13 with tumor load was found. On the basis of these results, the potential of sCD13 activity as a tumor and/or angiogenesis marker warrants further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0036899698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036899698&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 3747

EP - 3754

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -